Overview

Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and NurofenĀ®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting Conditions

Status:
Completed
Trial end date:
2018-06-25
Target enrollment:
Participant gender:
Summary
To demonstrate bioequivalence of single dose test formulation of Ibuprofen,oral suspension 200 mg/5 ml (containing ibuprofen 200 mg) of Pharmtechnology LLC, Republic of Belarus with reference NurofenĀ® for Children, oral suspension 100 mg / 5 ml (containing ibuprofen 100 mg) of "Reckitt Benckiser Healthcare International Ltd, .", UK in normal, healthy, adult, human subjects under fasting conditions.To monitor adverse events and ensure the safety
Phase:
Phase 1
Details
Lead Sponsor:
Pharmtechnology LLC
Collaborators:
ClinPharmInvest, LLC
CRO ClinPharmInvest
Treatments:
Ibuprofen